Crossmark

SARS-CoV-2-specific immune responses in elderly and immunosuppressed participants and patients with hematologic disease or checkpoint inhibition in solid tumors: study protocol of the prospective, observational CoCo immune study

Crossref DOI link: https://doi.org/10.1186/s12879-022-07347-w

Published Online: 2022-04-25

Published Print: 2022-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Dopfer-Jablonka, Alexandra

Steffens, Sandra

Müller, Frank

Mikuteit, Marie

Niewolik, Jacqueline

Cossmann, Anne

Stankov, Metodi V.

Behrens, Georg M. N.

Hummers, Eva

Heesen, Gloria

Schröder, Dominik http://orcid.org/0000-0002-3564-4725
Roder, Sascha

Klawonn, Frank

Vahldiek, Kai

Hasenkamp, Justin

Kallusky, Jonathan

Falk, Christine S.

Overbeck, Tobias R.

Heinemann, Stephanie
Funding

Funding for this research was provided by:

European Regional Development Fund (ZW7-85152953)

Förderschwerpunktprogramm des COVID-19 Forschungsnetzwerks Niedersachsen (8FT21)

Georg-August-Universität Göttingen
License Information

Text and Data Mining valid from 2022-04-25

Version of Record valid from 2022-04-25
More Information

Article History

Received: 20 March 2022

Accepted: 4 April 2022

First Online: 25 April 2022

Declarations

:

: Ethics vote was obtained from the Ethics Committee of the University Medical Center Göttingen (No. 29/3/21). The study is registered in the German Clinical Trials Register, an approved Primary Register in the WHO network (DRKS00023972). Informed consent is/was obtained written from all individual participants included in the study.

: Not applicable.

: The authors declare that they have no competing interests.

Document is current

Any future updates will be listed below